Health & Fitness
Health and Fitness
Health and Fitness
Wed, October 31, 2012Tue, October 30, 2012Mon, October 29, 2012Sun, October 28, 2012Fri, October 26, 2012Thu, October 25, 2012Wed, October 24, 2012Tue, October 23, 2012Mon, October 22, 2012Sun, October 21, 2012Sat, October 20, 2012Fri, October 19, 2012Thu, October 18, 2012Wed, October 17, 2012Tue, October 16, 2012Mon, October 15, 2012Sun, October 14, 2012Fri, October 12, 2012Thu, October 11, 2012Wed, October 10, 2012Tue, October 9, 2012Mon, October 8, 2012Sun, October 7, 2012Sat, October 6, 2012Fri, October 5, 2012Thu, October 4, 2012Uroplasty To Issue Second Quarter Of Fiscal 2013 Financial Results On October 25, 2012
Published in Health and Fitness on Wednesday, October 17th 2012 at 4:47 GMT by Market Wire
Uroplasty To Issue Second Quarter Of Fiscal 2013 Financial Results On October 25,... -- MINNEAPOLIS, Oct. 17, 2012 /PRNewswire/ --
MINNEAPOLIS, Oct. 17, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]) announced today that it will release financial results for the second quarter of fiscal 2013 ended September 30, 2012 at the market close on Thursday, October 25, 2012. The Company will host a conference call to discuss these results on Thursday, October 25, 2012 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen , President and Chief Executive Officer, and Medi Jiwani , Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-0843. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4568214#.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 |
EVC Group Doug Sherk (Investors), 415.652.9100 Jenifer Kirtland (Investors), 415.568.9349 Chris Gale (Media), 646.201.5431 |
SOURCE Uroplasty, Inc.
